Clinical Pharmacokinetics

, Volume 47, Issue 8, pp 515–531 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren

  • Sujata Vaidyanathan
  • Venkateswar Jarugula
  • Hans Armin Dieterich
  • Dan Howard
  • William P. Dole
Review Article

Abstract

Aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of hypertension. It acts at the point of activation of the renin-angiotensin-aldosterone system, or renin system, inhibiting the conversion of angiotensinogen to angiotensin I by renin and thereby reducing the formation of angiotensin II by angiotensin-converting enzyme (ACE) and ACE-independent pathways. Aliskiren is a highly potent inhibitor of human renin in vitro (concentration of aliskiren that produces 50% inhibition of renin 0.6 nmol/L). Aliskiren is rapidly absorbed following oral administration, with maximum plasma concentrations reached within 1–3 hours. The absolute bioavailability of aliskiren is 2.6%. The binding of aliskiren to plasma proteins is moderate (47–51%) and is independent of the concentration. Once absorbed, aliskiren is eliminated through the hepatobiliary route as unchanged drug and, to a lesser extent, through oxidative metabolism by cytochrome P450 (CYP) 3A4. Unchanged aliskiren accounts for approximately 80% of the drug in the plasma following oral administration, indicating low exposure to metabolites. The two major oxidized metabolites of aliskiren account for less than 5% of the drug in the plasma at the time of the maximum concentration. Aliskiren excretion is almost completely via the biliary/faecal route; 0.6% of the dose is recovered in the urine. Steady-state plasma concentrations of aliskiren are reached after 7–8 days of once-daily dosing, and the accumulation factor for aliskiren is approximately 2. After reaching the peak, the aliskiren plasma concentration declines in a multiphasic fashion.

No clinically relevant effects of gender or race on the pharmacokinetics of aliskiren are observed, and no adjustment of the initial aliskiren dose is required for elderly patients or for patients with renal or hepatic impairment. Aliskiren showed no clinically significant increases in exposure during coadministration with a wide range of potential concomitant medications, although increases in exposure were observed with P-glycoprotein inhibitors. Aliskiren does not inhibit or induce CYP isoenzyme or P-glycoprotein activity, although aliskiren is a substrate for P-glycoprotein, which contributes to its relatively low bioavailability.

Aliskiren is approved for the treatment of hypertension at once-daily doses of 150 mg and 300 mg. Phase II and III clinical studies involving over 12 000 patients with hypertension have demonstrated that aliskiren provides effective long-term blood pressure (BP) lowering with a good safety and tolerability profile at these doses. Aliskiren inhibits plasma renin activity (PRA) by up to 80% following both single and multiple oral-dose administration. Similar reductions in PRA are observed when aliskiren is administered in combination with agents that alone increase PRA, including diuretics (hydrochlorothiazide, furosemide [frusemide]), ACE inhibitors (ramipril) and angiotensin receptor blockers (valsartan), despite greater increases in the plasma renin concentration. Moreover, PRA inhibition and BP reductions persist for 2–4 weeks after stopping treatment, which is likely to be of benefit in patients with hypertension who occasionally miss a dose of medication.

Preliminary data on the antiproteinuric effects of aliskiren in type 2 diabetes mellitus suggest that renoprotective effects beyond BP lowering may be possible. Further studies to evaluate the effects of aliskiren on cardiovascular outcomes and target organ protection are ongoing and will provide important new data on the role of direct renin inhibition in the management of hypertension and other cardiovascular disease.

Keywords

Renin Valsartan Plasma Renin Activity Aliskiren Direct Renin Inhibitor 

Notes

Acknowledgements

All authors are employees of Novartis and are thus eligible for Novartis stock and stock options. All authors participated in the development and writing of this article and approved the final manuscript for publication. The authors take full responsibility for the content of the article and thank Andrew Mayhook (Oxford PharmaGenesis™ Ltd) for assistance in collating and incorporating comments from all authors to produce a final draft manuscript for submission. This work was funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

References

  1. 1.
    Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12 (12 Pt 3): 205S–13SPubMedCrossRefGoogle Scholar
  2. 2.
    Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003; 21(9): 1599–608PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16(3): 592–9PubMedCrossRefGoogle Scholar
  4. 4.
    Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24(2): 243–56PubMedCrossRefGoogle Scholar
  5. 5.
    Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80(2): 219–27PubMedCrossRefGoogle Scholar
  6. 6.
    Kahn JR, Lentz K, Skeggs Jr LT, et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106(3): 439–53PubMedCrossRefGoogle Scholar
  7. 7.
    Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308(4): 698–705PubMedCrossRefGoogle Scholar
  8. 8.
    Lefèvre G, Duval M, Poncin A. Direct micro-radioimmunoassay of the new renin inhibitor CGP 60536. J Immunoassay 2000; 21(1): 65–84PubMedCrossRefGoogle Scholar
  9. 9.
    Vaidyanathan S, Warren V, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47(2): 192–200PubMedCrossRefGoogle Scholar
  10. 10.
    Vaidyanathan S, Reynolds C, Yeh C-M, et al. The pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with the P-glycoprotein modulators ketoconazole, digoxin and atorvastatin in healthy subjects [abstract no. PIII-175]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S109Google Scholar
  11. 11.
    Vaidyanathan S, Reynolds C, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47(4): 453–60PubMedCrossRefGoogle Scholar
  12. 12.
    Vaidyanathan S, Jermany J, Yeh C-M, et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62(6): 690–8PubMedCrossRefGoogle Scholar
  13. 13.
    Nussberger J, Jensen C. The bioavailability of aliskiren (SPP100) administered as 2 ×37.5mg capsules and a 75mg oral solution compared to a 20mg intravenous administration in healthy male subjects. Basel: Speedel Pharma AG, 2001. (Data on file)Google Scholar
  14. 14.
    Vaidyanathan S, Limoges D, Yeh C-M, et al. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006; 79 (2 Suppl. S): P64CrossRefGoogle Scholar
  15. 15.
    Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006; 60(11): 1343–56PubMedCrossRefGoogle Scholar
  16. 16.
    Reynolds C, Vaidyanathan S, Dieterich H-A, et al. A randomized, open-label, single-dose, two-period, crossover study in healthy subjects to evaluate the effect of food on the SPP100 Final Market Image (FMI) tablet. Basel: Novartis Pharma AG, 2006. (Data on file)Google Scholar
  17. 17.
    Mann J, Dieterle W. Aliskiren: a phase I, open-label, randomised, balanced, three-period crossover single oral dose study to investigate the comparative bioavailability of two different formulations and the effect of food on the pharmacokinetics in healthy male and female subjects. Basel: Speedel Pharma AG, 2002. (Data on file)Google Scholar
  18. 18.
    Tekturna® (aliskiren) tablets 150 mg and 300 mg [US prescribing information; online]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2007 Dec. Available from URL: http://www.tekturna.com/index.jsp?usertrack.filter_applied=true&NovaId=1137599007196 [Accessed 2008 May 27]
  19. 19.
    Rasilez [EU summary of product characteristics; online]. Horsham: Novartis Europharm Limited, 2007 Sep 3. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm [Accessed 2008 May 27]
  20. 20.
    Waldmeier FJ, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35(8): 1418–28PubMedCrossRefGoogle Scholar
  21. 21.
    Data on file, Novartis Pharmaceuticals Corporation, 2007Google Scholar
  22. 22.
    Jin Y, Borell H. Identification of human cytochrome P450 enzymes involved in the oxidative metabolism of SPP100 (aliskiren). Basel: Novartis Pharma AG, 2005. (Data on file)Google Scholar
  23. 23.
    Vaidyanathan S, Bigler H, Yeh C-M, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46(8): 661–75PubMedCrossRefGoogle Scholar
  24. 24.
    Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the ATI receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15(12): 3126–33PubMedCrossRefGoogle Scholar
  25. 25.
    Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43(11): 527–35PubMedGoogle Scholar
  26. 26.
    Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39(1): E1–8PubMedCrossRefGoogle Scholar
  27. 27.
    Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49(11): 1157–63PubMedCrossRefGoogle Scholar
  28. 28.
    Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1(4): 264–77PubMedCrossRefGoogle Scholar
  29. 29.
    Data on file, Novartis Pharmaceuticals Corporation, 2006Google Scholar
  30. 30.
    Zhao C, Vaidyanathan S, Yeh C-M, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes. Clin Pharmacokinet 2006; 45(11): 1125–34PubMedCrossRefGoogle Scholar
  31. 31.
    Vaidyanathan S. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro [abstract]. Basic Res Pharmcol Toxicol 2005; 97 Suppl. 1: 239Google Scholar
  32. 32.
    Camenisch G. Determination of the interaction with the human MDR1, MRP2 and BCRP (MXR) transporters using the ATPase assay. Basel: Novartis Pharma AG, 2004. (Data on file)Google Scholar
  33. 33.
    Dieterich H-A, Warren V, Sabo R, et al. Lack of pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and pioglitazone or fenofibrate in healthy volunteers [abstract no. P220]. Basic Clin Pharmcol Toxicol 2007; 101 Suppl. 1: 135–6Google Scholar
  34. 34.
    Reynolds C, Vaidyanathan S, Dieterich H-A, et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract no. PIII-177]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S110Google Scholar
  35. 35.
    Urosevic D, Bartlett M, Costa AM, et al. Lack of pharmacokinetic interaction between aliskiren a direct oral renin inhibitor and isosorbide-5-mononitrate in healthy volunteers [abstract no. P032]. Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1: 63Google Scholar
  36. 36.
    Zhao C, Vaidyanathan S, Dieterich H-A, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-178]. Clin Pharmacol Ther 2007; 81 Suppl. 1: SUOGoogle Scholar
  37. 37.
    Ayalasomayajula S, Tchaloyan S, Yeh C-M, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008; 24(3): 717–20PubMedCrossRefGoogle Scholar
  38. 38.
    Achira M, Suzuki H, Ito K, et al. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999; 1(4): E18PubMedCrossRefGoogle Scholar
  39. 39.
    Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23(3): 506–12PubMedCrossRefGoogle Scholar
  40. 40.
    Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111(8): 1012–8PubMedCrossRefGoogle Scholar
  41. 41.
    Hariry S, Rebello S, Feng A, et al. An open-label, single-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (aliskiren) when given alone and in combination with cyclosporine to healthy subjects. Basel: Novartis Pharma AG, 2007. (Data on file)Google Scholar
  42. 42.
    Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 58(4): 433–6PubMedCrossRefGoogle Scholar
  43. 43.
    Homsy W, Marleau S, du Souich P. Furosemide dynamics in conscious rabbits: modulation by angiotensin II. Cardiovasc Drugs Ther 1995; 9(2): 311–7PubMedCrossRefGoogle Scholar
  44. 44.
    Bindschedler M, Degen P, Flesch G, et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997; 52(5): 371–8PubMedCrossRefGoogle Scholar
  45. 45.
    Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 1989; 2 (11 Pt 1): 819–27PubMedGoogle Scholar
  46. 46.
    DiaSorin. RENCTK assay information. Stillwater (MN): DiaSorin Inc., 2007Google Scholar
  47. 47.
    Nussberger J, Porchet M, Fasanella d’Amore T, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9(1): 39–44PubMedGoogle Scholar
  48. 48.
    Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61(9): 1461–8PubMedCrossRefGoogle Scholar
  49. 49.
    Menard J, Guyene TT, Peyrard S, et al. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006; 24(3): 529–34PubMedCrossRefGoogle Scholar
  50. 50.
    Lijnen P, Fagard R, Staessen J, et al. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981; 12(3): 387–92PubMedCrossRefGoogle Scholar
  51. 51.
    Taylor AA, Anderson DR, Arora V, et al. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension [abstract no. 1014-170]. J Am Coll Cardiol 2007; 49(9 Suppl. A): 370AGoogle Scholar
  52. 52.
    Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25(1): 217–26PubMedCrossRefGoogle Scholar
  53. 53.
    Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet 2007; 370(9583): 221–9PubMedCrossRefGoogle Scholar
  54. 54.
    Alderman MH, Cohen HW, Sealey JE, et al. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17(1): 1–7PubMedCrossRefGoogle Scholar
  55. 55.
    Frandsen E, Boomsma F, Persson F, et al. Aliskiren reduces renin system activity in patients with hypertension, type 2 diabetes and albuminuria [abstract]. American Society of Hypertension 23rd Annual Scientific Meeting; 2008 May 14–17; New Orleans (LA)Google Scholar
  56. 56.
    Feldman DL, Persohn E, Schutz H, et al. Renal localization of the renin inhibitor aliskiren [abstract no. P-78]. J Clin Hypertens 2006; 8(5): A80–1Google Scholar
  57. 57.
    Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42(6): 1137–43PubMedCrossRefGoogle Scholar
  58. 58.
    Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke 1998; 29(5): 992–6PubMedCrossRefGoogle Scholar
  59. 59.
    Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79(11): 1512–6PubMedCrossRefGoogle Scholar
  60. 60.
    Pool JL, Gradman AH, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract no. P-790]. Eur Heart J 2006; 27: 119Google Scholar
  61. 61.
    Keefe DL, Andersen K, Weinberger MH, et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor [abstract no. P-1014-204]. J Am Coll Cardiol 2007; 49(9 Suppl. A): 372AGoogle Scholar
  62. 62.
    Weinberger MH, Andersen K, Constance CM, et al. Aliskiren-based therapy provides long-term suppression of plasma renin activity that persists after treatment withdrawal in patients with hypertension [abstract no. P-1020-168]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 390A–1AGoogle Scholar
  63. 63.
    Fisher ND, Hollenberg NK. Unprecedented renal responses to direct blockade of the renin-angiotensin-system with aliskiren, a novel renin inhibitor [abstract]. Circulation 2007; 116 (16 Suppl.): 11–556Google Scholar
  64. 64.
    Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effect of direct renin inhibition with aliskiren in patients with type 2 diabetes and albuminuria [abstract no. F-PO1029]. J Am Soc Nephrol 2007; 18: 329AGoogle Scholar
  65. 65.
    Fisher NDL, Danser AHJ, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117(25): 3199–205PubMedCrossRefGoogle Scholar
  66. 66.
    Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 2008; 358(23): 2433–46PubMedCrossRefGoogle Scholar
  67. 67.
    McMurray JJV, Pitt, B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17–24PubMedCrossRefGoogle Scholar
  68. 68.
    Parving HH, Brenner BM, McMurray JJV, et al. ALiskiren Trial In Type 2 diabetes Using cardio-renal Disease Endpoints (ALTITUDE): rationale and study design [abstract no. PUB557]. J Am Soc Nephrol 2007; 18(Abstracts Issue): 952Google Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Sujata Vaidyanathan
    • 1
  • Venkateswar Jarugula
    • 1
  • Hans Armin Dieterich
    • 2
  • Dan Howard
    • 1
  • William P. Dole
    • 3
  1. 1.Novartis Pharmaceuticals CorporationEast HanoverUSA
  2. 2.Novartis Pharma AGBaselSwitzerland
  3. 3.Novartis Institutes for Biomedicai Research Inc.CambridgeUSA

Personalised recommendations